Published in Biochem J on June 01, 1997
Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol (1998) 2.22
A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate. J Nutr (2008) 1.22
Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol (2005) 1.14
Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol (2010) 1.11
EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling. J Mol Cell Cardiol (2010) 1.05
Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev (2012) 1.01
Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol (2007) 1.00
An insertion/deletion polymorphism of the dihydrofolate reductase (DHFR) gene is associated with serum and red blood cell folate concentrations in women. Hum Genet (2008) 0.93
Novel role of TGF-beta in differential astrocyte-TIMP-1 regulation: implications for HIV-1-dementia and neuroinflammation. J Neurosci Res (2006) 0.92
CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. J Neurochem (2011) 0.87
A novel mechanism of matrix metalloproteinase-9 gene expression implies a role for keratinization. EMBO Rep (2001) 0.85
Extracellular regulated kinase 1/2 signaling is a critical regulator of interleukin-1β-mediated astrocyte tissue inhibitor of metalloproteinase-1 expression. PLoS One (2013) 0.81
Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma. Cell Mol Immunol (2004) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res (1987) 15.65
The matrix-degrading metalloproteinases. Bioessays (1992) 4.84
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum (1994) 1.93
Characterization of a family of related cellular transcription factors which can modulate human immunodeficiency virus type 1 transcription in vitro. Mol Cell Biol (1994) 1.62
Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther (1993) 1.29
Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases. J Biol Chem (1993) 1.20
Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol (1993) 1.14
Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J Biol Chem (1996) 1.11
Developmental expression of the endogenous TIMP gene and a TIMP-lacZ fusion gene in transgenic mice. Genes Dev (1990) 1.07
Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J Biol Chem (1991) 1.06
Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta (1992) 1.04
Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. Nucleic Acids Res (1995) 1.04
Interleukin 6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts. Biochem Biophys Res Commun (1990) 0.99
Presence of transcription regulatory elements within an intron of the virus-inducible murine TIMP gene. Mol Cell Biol (1988) 0.98
Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene (1994) 0.97
Tissue inhibitor of metalloproteinases (TIMP-1) stimulates the secretion of collagenase from human skin fibroblasts. Biochem Biophys Res Commun (1994) 0.92
Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Biochem J (1995) 0.92
Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid-potentiating activity (tissue inhibitor of metalloproteinases-1, TIMP-1). J Biol Chem (1994) 0.88
Basal expression of the gene (TIMP) encoding the murine tissue inhibitor of metalloproteinases is mediated through AP1- and CCAAT-binding factors. Gene (1992) 0.85
The secretion of the tissue inhibitor of metalloproteinases (TIMP) by human synovial fibroblasts is modulated by all-trans-retinoic acid. Biochim Biophys Acta (1991) 0.84
Rapid transfer of DNA from agarose gels to nylon membranes. Nucleic Acids Res (1985) 21.05
Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci (2001) 3.71
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
MicroRNAs and the hallmarks of cancer. Oncogene (2006) 2.55
The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis (2005) 2.47
Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ (2006) 2.47
Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 2.39
Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J Cell Biol (1988) 2.37
Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology (2001) 2.25
Matrix metalloproteinases and diseases of the CNS. Trends Neurosci (1998) 2.24
Purification and characterization of a rabbit bone metalloproteinase that degrades proteoglycan and other connective-tissue components. Biochem J (1983) 2.17
Purification of rabbit bone inhibitor of collagenase. Biochem J (1981) 2.12
Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem (1994) 1.99
Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci (1999) 1.81
Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry (1995) 1.81
Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis (1989) 1.81
An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford) (2002) 1.74
Transcriptional regulation of two serum-induced RNAs in mouse fibroblasts: equivalence of one species to B2 repetitive elements. Mol Cell Biol (1985) 1.73
Rotator cuff degeneration and lateral epicondylitis: a comparative histological study. Ann Rheum Dis (1994) 1.73
The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J (1983) 1.72
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer (1999) 1.71
Signalling and superinduction. Nature (1991) 1.70
Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol (1997) 1.64
Metalloproteinases from rabbit bone culture medium degrade types IV and V collagens, laminin and fibronectin. Biochem J (1981) 1.62
The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum (1993) 1.62
Identification of the Nef-associated kinase as p21-activated kinase 2. Curr Biol (1999) 1.58
Tendon degeneration and chronic shoulder pain: changes in the collagen composition of the human rotator cuff tendons in rotator cuff tendinitis. Ann Rheum Dis (1994) 1.58
Fragments of human fibroblast collagenase. Purification and characterization. Biochem J (1989) 1.55
The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum (1998) 1.53
Purification of pig synovial collagenase to high specific activity. Biochem J (1979) 1.53
The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum (2002) 1.52
An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. Biochem J (1981) 1.52
Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett (1997) 1.49
TNFα from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis. Am J Transplant (2013) 1.46
Neurite outgrowth in response to transfected N-CAM and N-cadherin reveals fundamental differences in neuronal responsiveness to CAMs. Neuron (1991) 1.46
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer (2005) 1.45
Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. Structure (1995) 1.44
Glycosaminoglycans of human rotator cuff tendons: changes with age and in chronic rotator cuff tendinitis. Ann Rheum Dis (1994) 1.43
Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol (1998) 1.38
Gene expression during the mammalian cell cycle. Biochim Biophys Acta (1986) 1.37
Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36
Cancer. Proteases--invasion and more. Nature (1998) 1.34
Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer (1991) 1.34
Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax (2005) 1.33
Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations. Genes Dev (1990) 1.32
Characterization of the mouse met proto-oncogene. Oncogene (1988) 1.31
Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum (2001) 1.31
Metalloproteinases and collagenase inhibitors in rheumatoid synovial fluid. Arthritis Rheum (1984) 1.31
Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis (2002) 1.31
Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther (1993) 1.29
Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein. Nucleic Acids Res (1992) 1.27
Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol (1998) 1.27
A growth-responsive gene (16C8) in normal mouse fibroblasts homologous to a human collagenase inhibitor with erythroid-potentiating activity: evidence for inducible and constitutive transcripts. Nucleic Acids Res (1986) 1.25
Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum (2001) 1.24
Primary airway epithelial cell culture from lung transplant recipients. Eur Respir J (2005) 1.23
Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood (1999) 1.23
Characterization of a specific antiserum for mammalian collagenase from several species: immunolocalization of collagenase in rabbit chondrocytes and uterus. J Cell Sci (1986) 1.22
Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases. Ann Rheum Dis (1995) 1.22
Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology (1997) 1.21
Measurement of rheumatoid factors by an enzyme-linked immunosorbent assay (ELISA) and comparison with other methods. Ann Rheum Dis (1985) 1.20
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol (2013) 1.20
Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis (2008) 1.19
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol (2001) 1.19
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev Genet (1997) 1.18
Identification of the pathogenic pathways in osteoarthritic hip cartilage: commonality and discord between hip and knee OA. Osteoarthritis Cartilage (2012) 1.17
TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol (2001) 1.16
Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer (1992) 1.15
Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum (2003) 1.15
Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum (2001) 1.13
Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim Biophys Acta (1982) 1.13
Collagenase: a key enzyme in collagen turnover. Biochem Cell Biol (1996) 1.12
Activation of procathepsin B in human hepatoma cells: the conversion into the mature enzyme relies on the action of cathepsin B itself. Biochem J (1993) 1.12
Collagenase (MMP-1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis. Eye (Lond) (1995) 1.12
Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum (2006) 1.10
The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun (1994) 1.10
ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer (2011) 1.10
Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood (1991) 1.08
Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J (2001) 1.08
Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene (2006) 1.08
Prevalence and possible pathological significance of calcium phosphate salt accumulation in tendon matrix degeneration. Ann Rheum Dis (1996) 1.08
Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor. Development (1995) 1.08
Stem bromelain: amino acid sequence and implications for weak binding of cystatin. FEBS Lett (1989) 1.07
Monoclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure total collagenase. Matrix (1992) 1.07
Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis (2001) 1.06
Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer (2000) 1.06
Tenascin-C and human tendon degeneration. Am J Pathol (1996) 1.06